Substance P

Substance P is released from the terminals of C-fibre sensory neurons and acts principally at NK1 receptors. In the repair context it recruits CD29-positive mesenchymal stem cells from bone marrow to wound sites, promotes keratinocyte and endothelial proliferation, and is essential for corneal epithelial healing - which is why loss of corneal innervation causes neurotrophic keratopathy, and why a substance P derived peptide combined with IGF-1 has been used clinically in Japan as eye drops for that condition. The other half of its biology is why it is usually blocked rather than given: it mediates neurogenic inflammation, pain transmission, itch and vomiting, and NK1 antagonists such as aprepitant are the actual approved drugs in this pathway. Injecting substance P systemically reproduces flare, wheal, itch and hypotension, which is exactly what you would predict.

Targets: Neurokinin-1 receptor, Mast cell degranulation, CD29+ mesenchymal stem cell mobilisation, Corneal epithelial repair, Nociceptive signalling

• · There is no dosing protocol for substance P as a therapeutic. It is supplied in milligram research quantities for laboratory use, and the only clinical application is a compounded ophthalmic preparation of a substance P fragment with IGF-1 for neurotrophic keratopathy, prepared and prescribed by ophthalmologists. Anyone quoting you a subcutaneous substance P dose is making it up.

Work out your exact syringe units →

• very commonImmediate flare, wheal and intense itching at the injection site— This is the defining pharmacological response, not an idiosyncratic reaction.
• very commonPain— Substance P is a nociceptive transmitter; injecting it hurts by design.
• commonHypotension and flushing— From widespread mast cell degranulation and vasodilation.
• commonNausea and vomiting— The NK1 pathway is the emetic pathway - this is why NK1 antagonists are anti-nausea drugs.
• uncommonBronchoconstriction— A genuine risk in anyone with asthma or reactive airways.

• Asthma or any reactive airway disease - substance P is a bronchoconstrictor and mast cell degranulator.
• Mast cell activation syndrome, systemic mastocytosis or severe allergy history.
• Any systemic self-administration at all - there is no protocol, no established dose and a predictable adverse response.

• conflictNK1 antagonists such as aprepitant — Directly blocks the receptor; they cancel each other out.
• cautionAntihistamines — Blunt the mast cell mediated component but do not prevent the neurogenic or airway effects.

• · Not applicable for self-directed use.
• · In the ophthalmic setting, corneal healing is tracked by an ophthalmologist with slit lamp and staining.

Not an approved drug anywhere in an injectable form. Sold as a laboratory research reagent.

• Hong et al., substance P mobilises CD29+ mesenchymal stem cells and accelerates wound healing, Nature Medicine (preclinical)
• Nakamura et al., substance P derived peptide with IGF-1 in neurotrophic keratopathy (trial)
• Mashaghi et al., neuropeptide substance P and the immune response (review) (review)

Substance P is the prototypical tachykinin, released from the peripheral and central terminals of C-fibre sensory neurons, and it acts principally at the NK1 receptor - a Gq-coupled GPCR signalling through phospholipase C, IP3 and calcium release. The repair biology is genuine and interesting. Substance P mobilises CD29-positive stromal cells from bone marrow into the circulation and to wound sites, which was the finding that reframed it as an injury-inducible systemic messenger rather than purely a pain transmitter. It also promotes keratinocyte and endothelial proliferation, and it is essential for corneal epithelial healing - which is why loss of corneal innervation produces neurotrophic keratopathy, and why a substance P derived peptide combined with IGF-1 has been used clinically in Japan as eye drops for exactly that condition. The other half of the biology is the reason nobody injects it. NK1 activation on mast cells causes direct degranulation - histamine, tryptase, the full flare-and-wheal response. NK1 in the airway causes bronchoconstriction and plasma extravasation. NK1 in the area postrema is the emetic pathway, which is why aprepitant and the other NK1 antagonists are approved antiemetics. NK1 in the dorsal horn transmits nociception, so injecting substance P hurts as a matter of pharmacology rather than technique. That asymmetry is the entire clinical story of this molecule. Everywhere it has become a drug, it has become a drug by being blocked. Aprepitant, fosaprepitant and rolapitant are NK1 antagonists. There is no approved NK1 agonist for any indication, and the only clinical use of substance P itself is a compounded ophthalmic preparation of a fragment, applied topically to a cornea, prescribed by ophthalmologists. If someone offers you a subcutaneous substance P protocol, they are not describing a therapy that exists.

Everything you would predict goes wrong, immediately, because this is a molecule that evolved to signal tissue damage. At the injection site: flare, wheal and intense itching within seconds, plus pain, because substance P is the nociceptive transmitter. This is not an idiosyncratic reaction and it does not improve with technique. Systemically at any meaningful dose: flushing and hypotension from widespread mast cell degranulation and vasodilation, nausea and vomiting because NK1 is the emetic pathway, and bronchoconstriction in anyone with reactive airways. The last of these is the one that can be serious. The deeper failure is conceptual. The mechanism people are chasing - CD29-positive stromal cell mobilisation to wounds - is a real finding in animal models, but reproducing it by injecting the ligand systemically means activating NK1 receptors in the airway, the gut, the skin and the dorsal horn at the same time. There is no route by which you get the stem cell mobilisation without the rest, which is precisely why nobody has developed it as a drug. And the practical one: anyone quoting you a subcutaneous substance P dose is inventing it. There is no established human dose, no protocol and no supplier selling it as anything other than a laboratory reagent in milligram quantities.

• Neurokinin-1 receptor (NK1R / TACR1) — Substance P is the endogenous high-affinity ligand, binding in the sub-nanomolar to low-nanomolar range

  Gq-coupled calcium signalling. Produces neurogenic inflammation, pain transmission, vasodilation, plasma extravasation, emesis and mast cell degranulation - all at once, because the receptor is everywhere.

• Mast cells — NK1-mediated and also via direct MRGPRX2 activation at higher concentrations

  Degranulation with histamine and tryptase release. The immediate flare, wheal and itch at any injection site is this, and it is expected pharmacology rather than allergy.

• CD29-positive mesenchymal / stromal cells — Downstream of NK1 signalling

  Mobilisation from bone marrow into circulation and recruitment to wound sites. The genuine repair mechanism and the reason substance P appears in a regenerative encyclopedia at all.

• Corneal epithelium — NK1-mediated, synergistic with IGF-1

  Epithelial migration and wound closure. The only setting where a substance P derived preparation is used clinically.

• Airway smooth muscle — NK1 and NK2 mediated

  Bronchoconstriction and plasma extravasation. This is why asthma is a hard contraindication rather than a caution.

• No clinical trial of injected substance P as a repair agent exists in any indication None

  The clinical development in this pathway has gone entirely in the opposite direction: NK1 antagonists such as aprepitant are approved antiemetics. The only clinical use of substance P itself is a compounded ophthalmic preparation of a fragment combined with IGF-1 for neurotrophic keratopathy, used in Japan.

Seconds to minutes: the entire local response - flare, wheal, itch, pain. There is no build-up phase and no delayed onset. Minutes: systemic flushing, blood pressure drop and nausea if enough has been given. That is the timeline. There is no week-two assessment point, because there is no protocol to assess. In the ophthalmic setting, corneal epithelial healing with the substance P fragment plus IGF-1 preparation is tracked over days to weeks by slit lamp and fluorescein staining.

There is nothing to stack, because there is no protocol. The only combination with any clinical basis is the substance P fragment with IGF-1 in an ophthalmic preparation for neurotrophic keratopathy, and that is compounded and prescribed by an ophthalmologist rather than assembled by a user. Two interactions are worth knowing for the opposite reason - because they explain things people encounter elsewhere. NK1 antagonists such as aprepitant block this receptor outright, so they and substance P cancel. And both ACE inhibitors and neprilysin inhibitors raise endogenous substance P by blocking its degradation, which is the accepted explanation for the dry cough that makes people stop ACE inhibitors. Antihistamines blunt the mast cell component of a substance P reaction but do nothing about the neurogenic, nociceptive or bronchoconstrictor components. Pre-medicating does not make this safe; it makes one of several predictable problems quieter.

Against the rest of this class: substance P is the one entry here that is primarily a warning. The biology is genuinely regenerative, the pharmacology makes it undeliverable, and the drugs that emerged from this pathway are all antagonists. Against NK1 antagonists such as aprepitant: those are the approved drugs in this pathway, used for chemotherapy-induced nausea and vomiting. If you are looking at the NK1 receptor for any clinical reason, blocking it is the direction with medicines behind it. Against BPC-157 or TB-500 for wound healing: those at least have a plausible route of administration and a tolerable side effect profile. Substance P has neither. For neurotrophic keratopathy specifically: cenegermin, a recombinant human nerve growth factor eye drop, is an approved treatment in the US and EU with randomised trial evidence. That is the drug for this problem, not a compounded substance P fragment and certainly not an injection.

Not applicable. Substance P is sold as a laboratory research reagent in milligram quantities at research-reagent pricing, not as a consumer or clinical product. There is no monthly protocol to cost.

• ?No pharmacokinetic parameters exist for exogenous substance P administration beyond the sub-minute plasma half-life.
• ?The Japanese ophthalmic substance P fragment plus IGF-1 preparation could not be resolved to a specific indexed trial in this session, so its dosing and outcomes are described but unverified.
• ?The relative contribution of NK1 versus MRGPRX2 to the mast cell degranulation seen with exogenous substance P is not fully resolved.
• ?Whether the CD29-positive stromal cell mobilisation finding translates to humans at any tolerable dose has never been tested.
• ?No human dose, protocol or safety data exists for any systemic route.

• A new role of substance P as an injury-inducible messenger for mobilization of CD29(+) stromal-like cells Hong HS et al., Nature Medicine, 2009 · PMID 19270709

  The paper that established substance P as a systemic injury signal mobilising stromal cells. This is the finding that all repair-related interest in substance P traces back to.

• Effect of substance P on recovery from laser-induced retinal degeneration Hong HS et al., Wound Repair and Regeneration, 2015 · PMID 25682893

  Follow-up work from the same group extending the repair findings to retinal injury. Animal model.